Cargando…

Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant

Maintaining the efficacy of anti-CD19 chimeric antigen receptor modified (CAR) T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) relapse after allogeneic hematopoietic stem cell transplant (allo-HSCT) is an urgent problem. In this study, we aimed to compare the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qing, Lyu, Cuicui, Liu, Meijing, Wang, Jia, Mou, Nan, Jiang, Erlie, Zhang, Rongli, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996720/
https://www.ncbi.nlm.nih.gov/pubmed/36879459
http://dx.doi.org/10.1177/09636897231158155
_version_ 1784903106096529408
author Li, Qing
Lyu, Cuicui
Liu, Meijing
Wang, Jia
Mou, Nan
Jiang, Erlie
Zhang, Rongli
Deng, Qi
author_facet Li, Qing
Lyu, Cuicui
Liu, Meijing
Wang, Jia
Mou, Nan
Jiang, Erlie
Zhang, Rongli
Deng, Qi
author_sort Li, Qing
collection PubMed
description Maintaining the efficacy of anti-CD19 chimeric antigen receptor modified (CAR) T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) relapse after allogeneic hematopoietic stem cell transplant (allo-HSCT) is an urgent problem. In this study, we aimed to compare the efficacy of donor hematopoietic stem cell infusion (DSI) therapy and donor lymphocyte infusion (DLI) therapy as a maintenance therapy after R/R B-ALL patients achieved CR in anti-CD19-CAR T-cell therapy but relapsed after allo-HSCT. In total, 22 B-ALL patients who relapsed after allo-HSCT received anti-CD19-CAR T-cell therapy. Patients who responded to CAR T-cell therapy received DSI or DLI as maintenance therapy. We compared the clinical responses, acute graft versus host disease (aGVHD), expansion of CAR-T-cells, and adverse events between the two groups. In our study, 19 patients received DSI/DLI as maintenance therapy. After DSI/DLI therapy, progression-free survival and overall survival were higher in the DSI group than in the DLI group at 365 days. The grades I and II of aGVHD was observed in four patients (36.4%) in the DSI group. Only one patient developed grade II aGVHD in the DLI group. The peaks of CAR T-cells in the DSI group were higher than those in the DLI group. IL-6 and TNF-α levels increased again in nine of 11 patients after DSI but not in the DLI group. Our findings indicate that for B-ALL patients who relapse after allo-HSCT, DSI is a feasible maintenance therapy if CR is obtained with CAR-T-cell therapy.
format Online
Article
Text
id pubmed-9996720
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-99967202023-03-10 Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant Li, Qing Lyu, Cuicui Liu, Meijing Wang, Jia Mou, Nan Jiang, Erlie Zhang, Rongli Deng, Qi Cell Transplant Original Article Maintaining the efficacy of anti-CD19 chimeric antigen receptor modified (CAR) T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) relapse after allogeneic hematopoietic stem cell transplant (allo-HSCT) is an urgent problem. In this study, we aimed to compare the efficacy of donor hematopoietic stem cell infusion (DSI) therapy and donor lymphocyte infusion (DLI) therapy as a maintenance therapy after R/R B-ALL patients achieved CR in anti-CD19-CAR T-cell therapy but relapsed after allo-HSCT. In total, 22 B-ALL patients who relapsed after allo-HSCT received anti-CD19-CAR T-cell therapy. Patients who responded to CAR T-cell therapy received DSI or DLI as maintenance therapy. We compared the clinical responses, acute graft versus host disease (aGVHD), expansion of CAR-T-cells, and adverse events between the two groups. In our study, 19 patients received DSI/DLI as maintenance therapy. After DSI/DLI therapy, progression-free survival and overall survival were higher in the DSI group than in the DLI group at 365 days. The grades I and II of aGVHD was observed in four patients (36.4%) in the DSI group. Only one patient developed grade II aGVHD in the DLI group. The peaks of CAR T-cells in the DSI group were higher than those in the DLI group. IL-6 and TNF-α levels increased again in nine of 11 patients after DSI but not in the DLI group. Our findings indicate that for B-ALL patients who relapse after allo-HSCT, DSI is a feasible maintenance therapy if CR is obtained with CAR-T-cell therapy. SAGE Publications 2023-03-06 /pmc/articles/PMC9996720/ /pubmed/36879459 http://dx.doi.org/10.1177/09636897231158155 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Li, Qing
Lyu, Cuicui
Liu, Meijing
Wang, Jia
Mou, Nan
Jiang, Erlie
Zhang, Rongli
Deng, Qi
Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
title Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
title_full Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
title_fullStr Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
title_full_unstemmed Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
title_short Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
title_sort donor hematopoietic stem cell/lymphocyte maintenance treatment after car t-cell therapy in patients with b-cell acute lymphoblastic leukemia relapse following stem cell transplant
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996720/
https://www.ncbi.nlm.nih.gov/pubmed/36879459
http://dx.doi.org/10.1177/09636897231158155
work_keys_str_mv AT liqing donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant
AT lyucuicui donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant
AT liumeijing donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant
AT wangjia donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant
AT mounan donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant
AT jiangerlie donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant
AT zhangrongli donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant
AT dengqi donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant